195 related articles for article (PubMed ID: 29567511)
1. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.
Aptsiauri N; Ruiz-Cabello F; Garrido F
Curr Opin Immunol; 2018 Apr; 51():123-132. PubMed ID: 29567511
[TBL] [Abstract][Full Text] [Related]
2. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
3. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
[TBL] [Abstract][Full Text] [Related]
4. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
5. Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases.
de Miranda NF; Goudkade D; Jordanova ES; Tops CM; Hes FJ; Vasen HF; van Wezel T; Morreau H
Clin Cancer Res; 2012 Mar; 18(5):1237-45. PubMed ID: 22261803
[TBL] [Abstract][Full Text] [Related]
6. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
7. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.
Hilders CG; Munoz IM; Nooyen Y; Fleuren GJ
Gynecol Oncol; 1995 Jun; 57(3):366-75. PubMed ID: 7774840
[TBL] [Abstract][Full Text] [Related]
8. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
9. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
[TBL] [Abstract][Full Text] [Related]
10. MHC/HLA Class I Loss in Cancer Cells.
Garrido F
Adv Exp Med Biol; 2019; 1151():15-78. PubMed ID: 31140106
[TBL] [Abstract][Full Text] [Related]
11. Targeting HLA class I expression to increase tumor immunogenicity.
del Campo AB; Carretero J; Aptsiauri N; Garrido F
Tissue Antigens; 2012 Mar; 79(3):147-54. PubMed ID: 22309256
[TBL] [Abstract][Full Text] [Related]
12. Rejection versus escape: the tumor MHC dilemma.
Garrido F; Ruiz-Cabello F; Aptsiauri N
Cancer Immunol Immunother; 2017 Feb; 66(2):259-271. PubMed ID: 28040849
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
[TBL] [Abstract][Full Text] [Related]
14. The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.
Garrido F; Perea F; Bernal M; Sánchez-Palencia A; Aptsiauri N; Ruiz-Cabello F
Vaccines (Basel); 2017 Feb; 5(1):. PubMed ID: 28264447
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity in the HLA class I region in human pancreatic cancer.
Ryschich E; Cebotari O; Fabian OV; Autschbach F; Kleeff J; Friess H; Bierhaus A; Büchler MW; Schmidt J
Tissue Antigens; 2004 Dec; 64(6):696-702. PubMed ID: 15546343
[TBL] [Abstract][Full Text] [Related]
16. HLA Class-I Expression and Cancer Immunotherapy.
Garrido F
Adv Exp Med Biol; 2019; 1151():79-90. PubMed ID: 31140107
[TBL] [Abstract][Full Text] [Related]
17. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
18. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
19. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
